Influence of Apoptosis and Cell Cycle Regulator Proteins on Chemotherapy Response and Survival in Stage IIIA/IIIB NSCLC Patients  José L. Morero, MD,

Slides:



Advertisements
Similar presentations
Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Advertisements

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
Su K. Metcalfe, MD, MPH, Michael T
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
Volume 13, Issue 12, Pages (December 2012)
Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
SC17.02 Lung Cancer in China: Challenges and Perspectives
ALK FISH and IHC: You Cannot Have One without the Other
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival  Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Frank Detterbeck, MD  Journal of Thoracic Oncology 
Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.
Volume 13, Issue 12, Pages (December 2012)
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.
Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia  Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.
Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.
An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.
Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer  Masahiko Harada,
George Blumenschein, MD, John V. Heymach, MD, PhD 
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,
Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.
A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):
PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?  Steven G. Gray, PhD  Journal of Thoracic.
Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q
Erratum Journal of Thoracic Oncology
Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.
Mitotic Inhibitors Journal of Thoracic Oncology
Mirror Mirror on the Wall, Who Is the Fairest of Them All
Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey  Daniel Morgensztern, MD, Shean Huey Ng,
Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.
The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer  Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,
Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011)  Ellen.
Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies  Mary Linton B Peters, MD,
Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada  Marcy Winget, PhD, Jennifer.
Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View  Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,
Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases  Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,
Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J
Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J
International Thymic Malignancies Interest Group: A Way Forward
European Lung Cancer Conference (ELCC) 2016 Organisation
Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival  John P. Griffin, MD, Charles E.
Neal S Goldstein, MD  The Annals of Thoracic Surgery 
Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer
APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.
Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.
Sleeve Lobectomy as an Alternative Procedure to Pneumonectomy for Non-small Cell Lung Cancer  Joon Suk Park, MD, Hee Chul Yang, MD, Hong Kwan Kim, MD,
A Review of First-Line Treatment for Small-cell Lung Cancer
Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD 
Mark A. Socinski, MD  Journal of Thoracic Oncology 
Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer  Caroline.
Robert Comis, MD, The Passing of a “Lung Man”
Presentation transcript:

Influence of Apoptosis and Cell Cycle Regulator Proteins on Chemotherapy Response and Survival in Stage IIIA/IIIB NSCLC Patients  José L. Morero, MD, Claudia Poleri, MD, Claudio Martín, MD, Maximiliano Van Kooten, MD, Reynaldo Chacón, MD, Moisés Rosenberg, MD  Journal of Thoracic Oncology  Volume 2, Issue 4, Pages 293-298 (April 2007) DOI: 10.1097/01.JTO.0000263711.54073.fa Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Time to progression with respect to Ki67 pre-QT expression (high, 7/32 patients; low/moderate, 25/32 patients). Journal of Thoracic Oncology 2007 2, 293-298DOI: (10.1097/01.JTO.0000263711.54073.fa) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Time to progression with respect to p21 pre-chemo expression (high, 13/33 patients; low, 20/33). Journal of Thoracic Oncology 2007 2, 293-298DOI: (10.1097/01.JTO.0000263711.54073.fa) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions